Psychiatrienet - User contributions [en]

Vortioxetine-venlafaxine

2015-11-04T14:16:47Z

Anoek:

{{Drugswitch
| from = vortioxetine
| to = venlafaxine
| stop =
{{stopVortioxetine}}
| start =
{{washout8-14}}
* '''Day 15:''' start with 37,5 mg of venlafaxine.
{{Day22NoBloodlevelvortioxetine}}<ref name="vortiswitch"> {{Pubmed|24570588 |Katona et al. New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder. 2014 2014 Feb 19;10:349-54}}</ref> <ref name="informatorium">{{KNMP|vortioxetine}}</ref>
| info =
* {{theorSS}}
}}

Vortioxetine-trazodone

2015-11-04T14:16:30Z

Anoek:

{{Drugswitch
| from = vortioxetine
| to = trazodone
| stop =
{{stopVortioxetine}}
| start =
* No wash-out period is needed. <ref name="vortiswitch"> {{Pubmed|24570588 |Katona et al. New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder. 2014 2014 Feb 19;10:349-54}}</ref> <ref name="informatorium">{{KNMP|vortioxetine}}</ref>
* '''Day 9:''' start trazodone in a dosage of 100-150 mg/day.
* If necessary, increase the dosage of trazodone gradually to a maximum of 400 mg/day.
| info =
* {{theorSS}}
}}

Vortioxetine-tranylcypromine

2015-11-04T14:16:13Z

Anoek:

{{Drugswitch
| from = vortioxetine
| to = tranylcypromine
| stop =
{{stopVortioxetine}}
| start =
* '''Day 8-21:''' a wash-out period of two weeks is necessary.<ref name="vortiswitch"> {{Pubmed|24570588 |Katona et al. New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder. 2014 2014 Feb 19;10:349-54}}</ref> <ref name="informatorium">{{KNMP|vortioxetine}}</ref>
* '''Day 22:''' Start administration of tranylcypromine in low dosage of 20 mg/day for one week.
* '''Day 29:''' after this week the dosage of tranylcypromine can be increased if necessary.
| caveat =
{{caveSS}}
}}

Vortioxetine-sertraline

2015-11-04T14:15:45Z

Anoek:

{{Drugswitch
| from = vortioxetine
| to = sertraline
| stop =
{{stopVortioxetine}}
| start =
* ''' Day 8-14: ''' a wash-out period of 1 week is necessary, because of CYP2D6-inhibition and serotonergic actions. <ref name="vortiswitch"> {{Pubmed|24570588 |Katona et al. New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder. 2014 2014 Feb 19;10:349-54}}</ref> <ref name="informatorium">{{KNMP|vortioxetine}}</ref>
* '''Day 15:''' Start sertraline in a normal dosage of 50 mg/day.
| info =
* {{theorSS}}
* Sertraline is a strong inhibitor of CYP2D6, which metabolizes vortioxetine. }}

Vortioxetine-paroxetine

2015-11-04T14:15:25Z

Anoek:

{{Drugswitch
| from = vortioxetine
| to = paroxetine
| stop =
{{stopVortioxetine}}
| start =
{{washout8-14}}
* '''Day 15:''' start administration of paroxetine in a normal dosage of 10-20 mg/day. <ref name="vortiswitch"> {{Pubmed|24570588 |Katona et al. New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder. 2014 2014 Feb 19;10:349-54}}</ref> <ref name="informatorium">{{KNMP|vortioxetine}}</ref>
| info =
* {{theorSS}}
* Paroxetine is a strong inhibitor of CYP2D6, which metabolizes vortioxetine. }}

Vortioxetine-nortriptyline

2015-11-04T14:15:11Z

Anoek:

{{Drugswitch
| from = vortioxetine
| to = nortriptyline
| stop =
{{stopVortioxetine}}
| start =
{{washout8-14}}
* '''Day 15:''' start administration of nortriptyline in a low dosage of 25 mg/day.
{{Day22NoBloodlevelvortioxetine}} <ref name="vortiswitch"> {{Pubmed|24570588 |Katona et al. New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder. 2014 2014 Feb 19;10:349-54}}</ref> <ref name="informatorium">{{KNMP|vortioxetine}}</ref>

|info =
* {{theorSS}}
}}

Vortioxetine-moclobemide

2015-11-04T14:10:11Z

Anoek:

{{Drugswitch
| from = vortioxetine
| to = moclobemide
| stop =
{{stopVortioxetine}}
| start =
* '''Day 8-23:''' a wash-out period of 2 weeks is necessary. <ref name="vortiswitch"> {{Pubmed|24570588 |Katona et al. New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder. 2014 2014 Feb 19;10:349-54}}</ref> <ref name="informatorium">{{KNMP|vortioxetine}}</ref>
* '''Day 24:''' start administration of moclobemide in normal dosage of 300 mg/day.
| caveat = {{caveSS}}
}}

Vortioxetine-mirtazapine

2015-11-04T14:09:53Z

Anoek:

{{Drugswitch
| from = vortioxetine
| to = mirtazapine
| stop =
{{stopVortioxetine}}<ref name="vortiswitch"> {{Pubmed|24570588 |Katona et al. New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder. 2014 2014 Feb 19;10:349-54}}</ref> <ref name="informatorium">{{KNMP|vortioxetine}}</ref>
| start =
* '''Day 9:''' start mirtazapine in a normal dosage of 15-30 mg/day.
| info =
* Mirtazapine is a very weak inhibitor of CYP2D6.

}}

Vortioxetine-maprotiline

2015-11-04T14:09:35Z

Anoek:

{{Drugswitch
| from = vortioxetine
| to = maprotiline
| stop =
{{stopVortioxetine}}<ref name="vortiswitch"> {{Pubmed|24570588 |Katona et al. New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder. 2014 2014 Feb 19;10:349-54}}</ref> <ref name="informatorium">{{KNMP|vortioxetine}}</ref>
| start =
* '''Day 9:''' start administration of maprotiline in a low dosage of 25 mg/day.
| info =
* {{theorSS}}
}}

Vortioxetine-imipramine

2015-11-04T14:08:02Z

Anoek:

{{Drugswitch
| from = vortioxetine
| to = imipramine
| stop =
{{stopVortioxetine}}
| start =
{{washout8-14}}
* '''Day 15:''' Start administration of imipramine in a low dosage of 25 mg/day.
{{Day22NoBloodlevelvortioxetine}}<ref name="vortiswitch"> {{Pubmed|24570588 |Katona et al. New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder. 2014 2014 Feb 19;10:349-54}}</ref> <ref name="informatorium">{{KNMP|vortioxetine}}</ref>
| info =
* {{theorSS}}
}}

Vortioxetine-hypericum

2015-11-04T14:07:40Z

Anoek:

{{Drugswitch
| from = vortioxetine
| to = hypericum
| stop =
{{stopVortioxetine}}
| start =
* '''Day 8-16:''' a wash-out period of 1 week is necessary.
* '''Day 17:''' start administration of hypericum in a dosage of 300 mg three times a day (900 mg/day).<ref>{{Pubmed|18294328|Imai H, Kotegawa T, Tsutsumi K, Morimoto T, Eshima N, Nakano S, Ohashi K. The recovery time-course of CYP3A after induction by St John's wort administration. Br J Clin Pharmacol. 2008 May;65(5):701-7.}}</ref><ref>{{Pubmed|16640452|Wurglics M, Schubert-Zsilavecz M. Hypericum perforatum: a 'modern' herbal antidepressant: pharmacokinetics of active ingredients. Clin Pharmacokinet. 2006;45(5):449-68.}}</ref><ref>{{Pubmed|19593191|Derijks HJ, Janknegt R, Heerdink ER, De Koning FH, Krekels MM, Looij BJ, Egberts AC. Influence of antidepressant use on glycemic control in patients with diabetes mellitus: an open-label comparative study. J Clin Psychopharmacol. 2009 Aug;29(4):405-8.}}</ref><ref name="vortiswitch"> {{Pubmed|24570588 |Katona et al. New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder. 2014 2014 Feb 19;10:349-54}}</ref><ref name="informatorium">{{KNMP|vortioxetine}}</ref>

| caveat =
{{caveSS}} {{Lit-SSRI-Hypericum}} {{Lit-SSRI-Hypericum2}}
| info = {{HypericumInfo}}
}}

Vortioxetine-hypericum

2015-11-04T14:07:05Z

Anoek:

{{Drugswitch
| from = vortioxetine
| to = hypericum
| stop =
{{stopVortioxetine}}
| start =
* '''Day 8-16:''' a wash-out period of 1 week is necessary.
* '''Day 17:''' start administration of hypericum in a dosage of 300 mg three times a day (900 mg/day).<ref>{{Pubmed|18294328|Imai H, Kotegawa T, Tsutsumi K, Morimoto T, Eshima N, Nakano S, Ohashi K. The recovery time-course of CYP3A after induction by St John's wort administration. Br J Clin Pharmacol. 2008 May;65(5):701-7.}}</ref><ref>{{Pubmed|16640452|Wurglics M, Schubert-Zsilavecz M. Hypericum perforatum: a 'modern' herbal antidepressant: pharmacokinetics of active ingredients. Clin Pharmacokinet. 2006;45(5):449-68.}}</ref><ref>{{Pubmed|19593191|Derijks HJ, Janknegt R, Heerdink ER, De Koning FH, Krekels MM, Looij BJ, Egberts AC. Influence of antidepressant use on glycemic control in patients with diabetes mellitus: an open-label comparative study. J Clin Psychopharmacol. 2009 Aug;29(4):405-8.}}</ref><ref name="informatorium">{{KNMP|hypericum}}</ref> <ref name="vortiswitch"> {{Pubmed|24570588 |Katona et al. New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder. 2014 2014 Feb 19;10:349-54}}</ref><ref name="informatorium">{{KNMP|vortioxetine}}</ref>

| caveat =
{{caveSS}} {{Lit-SSRI-Hypericum}} {{Lit-SSRI-Hypericum2}}
| info = {{HypericumInfo}}
}}

Vortioxetine-hypericum

2015-11-04T14:06:35Z

Anoek:

{{Drugswitch
| from = vortioxetine
| to = hypericum
| stop =
{{stopVortioxetine}}
| start =
* '''Day 8-16:''' a wash-out period of 1 week is necessary.
* '''Day 17:''' start administration of hypericum in a dosage of 300 mg three times a day (900 mg/day).<ref>{{Pubmed|18294328|Imai H, Kotegawa T, Tsutsumi K, Morimoto T, Eshima N, Nakano S, Ohashi K. The recovery time-course of CYP3A after induction by St John's wort administration. Br J Clin Pharmacol. 2008 May;65(5):701-7.}}</ref><ref>{{Pubmed|16640452|Wurglics M, Schubert-Zsilavecz M. Hypericum perforatum: a 'modern' herbal antidepressant: pharmacokinetics of active ingredients. Clin Pharmacokinet. 2006;45(5):449-68.}}</ref><ref>{{Pubmed|19593191|Derijks HJ, Janknegt R, Heerdink ER, De Koning FH, Krekels MM, Looij BJ, Egberts AC. Influence of antidepressant use on glycemic control in patients with diabetes mellitus: an open-label comparative study. J Clin Psychopharmacol. 2009 Aug;29(4):405-8.}}</ref><ref name="informatorium">{{KNMP|hypericum}}</ref> <ref name="vortiswitch"> {{Pubmed|24570588 |Katona et al. New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder. 2014 2014 Feb 19;10:349-54}}</ref> <ref name="informatorium">{{KNMP|vortioxetine}}</ref>

| caveat =
{{caveSS}} {{Lit-SSRI-Hypericum}} {{Lit-SSRI-Hypericum2}}
| info = {{HypericumInfo}}
}}

Vortioxetine-hypericum

2015-11-04T14:06:14Z

Anoek:

{{Drugswitch
| from = vortioxetine
| to = hypericum
| stop =
{{stopVortioxetine}}
| start =
* '''Day 8-16:''' a wash-out period of 1 week is necessary.
* '''Day 17:''' start administration of hypericum in a dosage of 300 mg three times a day (900 mg/day).<ref>{{Pubmed|18294328|Imai H, Kotegawa T, Tsutsumi K, Morimoto T, Eshima N, Nakano S, Ohashi K. The recovery time-course of CYP3A after induction by St John's wort administration. Br J Clin Pharmacol. 2008 May;65(5):701-7.}}</ref><ref>{{Pubmed|16640452|Wurglics M, Schubert-Zsilavecz M. Hypericum perforatum: a 'modern' herbal antidepressant: pharmacokinetics of active ingredients. Clin Pharmacokinet. 2006;45(5):449-68.}}</ref><ref>{{Pubmed|19593191|Derijks HJ, Janknegt R, Heerdink ER, De Koning FH, Krekels MM, Looij BJ, Egberts AC. Influence of antidepressant use on glycemic control in patients with diabetes mellitus: an open-label comparative study. J Clin Psychopharmacol. 2009 Aug;29(4):405-8.}}</ref><ref name="informatorium">{{KNMP|citalopram}}</ref> <ref name="vortiswitch"> {{Pubmed|24570588 |Katona et al. New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder. 2014 2014 Feb 19;10:349-54}}</ref> <ref name="informatorium">{{KNMP|vortioxetine}}</ref>

| caveat =
{{caveSS}} {{Lit-SSRI-Hypericum}} {{Lit-SSRI-Hypericum2}}
| info = {{HypericumInfo}}
}}

Vortioxetine-fluvoxamine

2015-11-04T14:05:41Z

Anoek:

{{Drugswitch
| from = vortioxetine
| to = fluvoxamine
| stop =
{{stopVortioxetine}}
| start =
* '''Day 8:''' start administration of fluvoxamine in a dosage of 50 mg/day.
{{Day22NoBloodlevelvortioxetine}}<ref name="vortiswitch"> {{Pubmed|24570588 |Katona et al. New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder. 2014 2014 Feb 19;10:349-54}}</ref> <ref name="informatorium">{{KNMP|vortioxetine}}</ref>
| info =
* {{theorSS}}
* Fluvoxamine is a inhibitor of CYP2C9, which metabolizes vortioxetine.

}}

Vortioxetine-fluoxetine

2015-11-04T14:05:24Z

Anoek:

{{Drugswitch
| from = vortioxetine
| to = fluoxetine
| stop =
{{stopVortioxetine}}
| start =
* A wash-out period of 2 weeks is necessary, because of CYP2D6-inhibition.
* '''Day 23:''' start administration of fluoxetine in a normal dosage of 20 mg/day.
| info =
* {{theorSS}}
* Fluoxetine is a strong inhibitor of CYP2D6, which metabolizes vortioxetine.
<ref name="vortiswitch"> {{Pubmed|24570588 |Katona et al. New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder. 2014 2014 Feb 19;10:349-54}}</ref> <ref name="informatorium">{{KNMP|vortioxetine}}</ref> }}

Vortioxetine-escitalopram

2015-11-04T14:05:04Z

Anoek:

{{Drugswitch
| from = vortioxetine
| to = escitalopram
| stop =
{{stopVortioxetine}}
| start =
* No wash-out period is needed.
* '''Day 9:''' start escitalopram in a normal dosage of 10 mg/day.
| info =
* {{theorSS}}
<ref name="vortiswitch"> {{Pubmed|24570588 |Katona et al. New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder. 2014 2014 Feb 19;10:349-54}}</ref> <ref name="informatorium">{{KNMP|vortioxetine}}</ref>
}}

Vortioxetine-duloxetine

2015-11-04T14:04:47Z

Anoek:

{{Drugswitch
| from = vortioxetine
| to = duloxetine
| stop =
{{stopVortioxetine}}
| start =
{{washout8-14}}
* '''Day 15:''' start administration of duloxetine in a dosage of 30 mg/day.
{{Day22NoBloodlevelvortioxetine}}<ref name="vortiswitch"> {{Pubmed|24570588 |Katona et al. New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder. 2014 2014 Feb 19;10:349-54}}</ref> <ref name="informatorium">{{KNMP|vortioxetine}}</ref>
| info =
* {{theorSS}}
* Duloxetine is a inhibitor of CYP2D6, which metabolizes vortioxetine.<ref>[[European Medicines Agency]] | SmPC Brintellix 5 mg. </ref>
}}

Vortioxetine-clomipramine

2015-11-04T14:04:21Z

Anoek:

{{Drugswitch
| from = vortioxetine
| to = clomipramine
| stop =
{{stopVortioxetine}}
| start =
* No wash-out period is needed.
* ''' Day 9:''' start with 25 mg/day of clomipramine.
{{GoSlow}}
{{Day22NoBloodlevelvortioxetine}}<ref name="vortiswitch"> {{Pubmed|24570588 |Katona et al. New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder. 2014 2014 Feb 19;10:349-54}}</ref> <ref name="informatorium">{{KNMP|vortioxetine}}</ref>
| info =
* {{theorSS}}<ref>[[European Medicines Agency]] | SmPC Brintellix 5 mg. </ref>

}}

Vortioxetine-citalopram

2015-11-04T14:03:50Z

Anoek:

{{Drugswitch
| from = vortioxetine
| to = citalopram
| stop =
{{stopVortioxetine}}
| start =
* No wash-out period is needed.
* '''Day 9:''' Start citalopram in a normal dosage of 20 mg/day.
| info =
* {{theorSS}}<ref>[http://www.ema.europa.eu/docs/nl_NL/document_library/EPAR_-_Product_Information/human/002717/WC500159449.pdf European Medicines Agency. SmPC Brintellix 5 mg.]</ref>
{{AutomaticCrosstapering}}<ref name="vortiswitch"> {{Pubmed|24570588 |Katona et al. New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder. 2014 2014 Feb 19;10:349-54}}</ref> <ref name="informatorium">{{KNMP|vortioxetine}}</ref>
}}

Vortioxetine-bupropion

2015-11-04T14:03:32Z

Anoek:

{{Drugswitch
| from = vortioxetine
| to = bupropion
| stop =
{{stopVortioxetine}}
| start =
* '''Day 9:''' start administration of bupropion in a dosage of 150 mg/day.
| info =
* Bupropion is a strong inhibitor of CYP2D6, which metabolizes vortioxetine. Combination of vortioxetine and bupropion can lead to adverse effects of vortioxetine.
* Vortioxetine has a biological half-life of 66 hours. Reduction to the lowest effective dose of vortioxetine probably prevents adverse effects of vortioxetine due to lower blood levels of vortioxetine. After 1 week at 5 mg vortioxetine, interaction with bupropion will not be dangerous. <ref name="vortiswitch"> {{Pubmed|24570588 |Katona et al. New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder. 2014 2014 Feb 19;10:349-54}}</ref> <ref name="informatorium">{{KNMP|vortioxetine}}</ref>
}}

Vortioxetine-agomelatine

2015-11-04T14:03:00Z

Anoek:

{{Drugswitch
| from = Vortioxetine
| to = agomelatine
| stop =
| stop =
{{stopVortioxetine}}
| start =
* '''Day 9:''' start administration of agomelatine in a dosage of 25 mg/day.
* '''Day 23:''' if necessary, increase dosage of agomelatine to 50 mg/day.<ref name="agoswitch"> {{Pubmed|20196187|McAllister-Williams RH et al. The use of antidepressants in clinical practice: focus on agomelatine. Hum Psychopharmacol. 2010 Mar 1;25(2):95-102}}</ref>
<ref name="vortiswitch"> {{Pubmed|24570588 |Katona et al. New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder. 2014 2014 Feb 19;10:349-54}}</ref> <ref name="informatorium">{{KNMP|vortioxetine}}</ref>
}}

Vortioxetine-amitriptyline

2015-11-04T13:53:41Z

Anoek:

{{ Drugswitch
| from = vortioxetine
| to = amitriptyline
| stop =
{{stopVortioxetine}}
| start =
* No wash-out period is needed.
* '''Day 9:''' start administration of amitriptyline in a dosage of 25 mg/day.
* '''Day 16:''' continue administration of amitriptyline in a dosage of 50 mg/day.
{{Day22NoBloodlevelvortioxetine}} <ref name="vortiswitch"> {{Pubmed|24570588 |Katona et al. New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder. 2014 2014 Feb 19;10:349-54}}</ref> <ref name="informatorium">{{KNMP|vortioxetine}}</ref>

| info =
* {{theorSS}}
}}

Vortioxetine-amitriptyline

2015-11-04T13:49:01Z

Anoek:

Vortioxetine-imipramine

2015-11-04T13:00:21Z

Anoek:

Vortioxetine-venlafaxine

2015-11-04T12:59:49Z

Anoek:

Vortioxetine-trazodone

2015-11-04T12:59:10Z

Anoek:

{{Drugswitch
| from = vortioxetine
| to = trazodone
| stop =
{{stopVortioxetine}}
| start =
* No wash-out period is needed.
* '''Day 9:''' start trazodone in a dosage of 100-150 mg/day.
* If necessary, increase the dosage of trazodone gradually to a maximum of 400 mg/day.
| info =
* {{theorSS}}
}}

Vortioxetine-duloxetine

2015-11-04T12:58:42Z

Anoek:

{{Drugswitch
| from = vortioxetine
| to = duloxetine
| stop =
{{stopVortioxetine}}
| start =
{{washout8-14}}
* '''Day 15:''' start administration of duloxetine in a dosage of 30 mg/day.
{{Day22NoBloodlevelvortioxetine}}
| info =
* {{theorSS}}
* Duloxetine is a inhibitor of CYP2D6, which metabolizes vortioxetine.<ref>[[European Medicines Agency]] | SmPC Brintellix 5 mg. </ref>
}}

Vortioxetine-clomipramine

2015-11-04T12:58:07Z

Anoek:

Vortioxetine-nortriptyline

2015-11-04T12:57:39Z

Anoek:

Vortioxetine-nortriptyline

2015-11-04T12:57:22Z

Anoek:

Vortioxetine-maprotiline

2015-11-04T12:56:46Z

Anoek:

{{Drugswitch
| from = vortioxetine
| to = maprotiline
| stop =
{{stopVortioxetine}}
| start =
* '''Day 9:''' start administration of maprotiline in a low dosage of 25 mg/day.
| info =
* {{theorSS}}
}}

Vortioxetine-maprotiline

2015-11-04T12:56:24Z

Anoek:

{{Drugswitch
| from = vortioxetine
| to = maprotiline
| stop =
{{stopVortioxetine}}
| start =
* '''Day 9:''' start administration of maprotiline in a low dosage of 25 mg/day.
| info =
{{theorSS}}
}}

Vortioxetine-doxepine

2015-11-04T12:55:47Z

Anoek:

{{Drugswitch
| from = vortioxetine
| to = doxepine
| stop =
{{stopVortioxetine}}
| start =
* '''Day 9:''' start administration of doxepin in a normal dosage of 25 mg/day.
{{Day22NoBloodlevelvortioxetine}}
| info =
* {{theorSS}}<ref>[[European Medicines Agency]] | SmPC Brintellix 5 mg. </ref>
}}

Vortioxetine-dosulepine

2015-11-04T12:55:15Z

Anoek:

{{Drugswitch
| from = vortioxetine
| to = dosulepine
| stop =
{{stopVortioxetine}}
| start =
* '''Day 9:''' start administration of dosulepine with 25 mg/day.
{{GoSlow}}
{{Day22NoBloodlevelvortioxetine}}
| info =
* {{theorSS}}<ref>[[European Medicines Agency]] | SmPC Brintellix 5 mg. </ref>
}}

Vortioxetine-amitriptyline

2015-11-04T12:54:43Z

Anoek:

Vortioxetine-amitriptyline

2015-11-04T12:54:32Z

Anoek:

{{ Drugswitch
| from = vortioxetine
| to = amitriptyline
| stop =
{{stopVortioxetine}}
| start =
No wash-out period is needed.
* '''Day 9:''' start administration of amitriptyline in a dosage of 25 mg/day.
* '''Day 16:''' continue administration of amitriptyline in a dosage of 50 mg/day.
{{Day22NoBloodlevelvortioxetine}}
| info =
* {{theorSS}}
}}

Vortioxetine-sertraline

2015-11-04T12:53:56Z

Anoek:

{{Drugswitch
| from = vortioxetine
| to = sertraline
| stop =
{{stopVortioxetine}}
| start =
* ''' Day 8-14: ''' a wash-out period of 1 week is necessary, because of CYP2D6-inhibition and serotonergic actions.
* '''Day 15:''' Start sertraline in a normal dosage of 50 mg/day.
| info =
* {{theorSS}}
* Sertraline is a strong inhibitor of CYP2D6, which metabolizes vortioxetine. }}

Vortioxetine-paroxetine

2015-11-04T12:53:09Z

Anoek:

Vortioxetine-paroxetine

2015-11-04T12:53:00Z

Anoek:

{{Drugswitch
| from = vortioxetine
| to = paroxetine
| stop =
{{stopVortioxetine}}
| start =
{{washout8-14}}
* '''Day 16:''' start administration of paroxetine in a normal dosage of 10-20 mg/day.
| info =
* {{theorSS}}
* Paroxetine is a strong inhibitor of CYP2D6, which metabolizes vortioxetine. }}

Vortioxetine-paroxetine

2015-11-04T12:52:46Z

Anoek:

{{Drugswitch
| from = vortioxetine
| to = paroxetine
| stop =
{{stopVortioxetine}}
| start =
{{washout9-15}}
* '''Day 16:''' start administration of paroxetine in a normal dosage of 10-20 mg/day.
| info =
* {{theorSS}}
* Paroxetine is a strong inhibitor of CYP2D6, which metabolizes vortioxetine. }}

Vortioxetine-fluvoxamine

2015-11-04T12:50:07Z

Anoek:

Vortioxetine-fluvoxamine

2015-11-04T12:49:44Z

Anoek:

Vortioxetine-fluoxetine

2015-11-04T12:49:15Z

Anoek:

Vortioxetine-escitalopram

2015-11-04T12:48:37Z

Anoek:

Vortioxetine-citalopram

2015-11-04T12:48:12Z

Anoek:

Imipramine-vortioxetine

2015-11-04T12:47:31Z

Anoek:

{{Drugswitch
| from = imipramine
| to = vortioxetine
| stop =
{{stopImipramine}}
| start =
* A wash-out period is not necessary.
* '''Day 9:''' start administration of vortioxetine in a low dosage of 10 mg/day.
| info =
* {{theorSS}}
}}

Imipramine-venlafaxine

2015-11-04T12:46:44Z

Anoek:

{{Drugswitch
| from = imipramine
| to = venlafaxine
| stop =
{{stopImipramine}}
| start =
* '''Day 9:''' {{startVenla}}
| info =
* {{theorSS}}
}}

Imipramine-trazodone

2015-11-04T12:46:02Z

Anoek:

{{Drugswitch
| from = imipramine
| to = trazodone
| stop =
{{stopImipramine}}
| start =
No wash-out period is needed.
* '''Day 4:''' simultaneously start administration of trazodone in a dosage of 150 mg/day.
* '''Day 8:''' continue administration of trazodone. {{upTrazo}}
| info =
* {{theorSS}}
}}

Imipramine-duloxetine

2015-11-04T12:45:03Z

Anoek:

{{Drugswitch
| from = imipramine
| to = duloxetine
| stop =
{{stopImipramine}}
| start =
* '''Day 4:''' simultaneously start administration of duloxetine in a normal dosage of 60 mg/day.
* '''Day 8:''' stop administration of imipramine and continue administration of duloxetine.
| info =
* {{theorSS}}
* Duloxetine is a inhibitor of CYP2D6, which metabolizes imipramine.
}}